Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

Phase 2 Recruiting 42 enrolled University of Colorado, Denver Alzheimer's Association · collab National Institute on Aging (NIA) · collab Partner Therapeutics, Inc. · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

A medicine that is FDA-approved for bone marrow stimulation (called sargramostim) will be tested for its safety and efficacy in individuals with mild-to-moderate Alzheimer's disease over a six month treatment period.

Timeline

Start: 2022-06-01
Primary completion: 2026-11-30
Completion: 2026-11-30

Publications

Results Potter H, Woodcock JH, Boyd TD, Coughlan CM, O'Shaughnessy JR, Borges MT, Thaker AA, Raj BA, Adamszuk K, Scott D, Adame V, Anton P, Chial HJ, Gray H, Daniels J, Stocker ME, Sillau SH. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease. Alzheimers Dement (N Y). 2021 Mar 24;7(1):e12158. doi: 10.1002/trc2.12158. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	sargramostim	Protein / enzyme biologic	178.57 ug/m2	Subcutaneous

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

Summary

Timeline

Publications

Drugs

Indications